Hummingbird Bioscience CEO Piers Ingram (L) and Synaffix CEO Peter van de Sande
Hummingbird and Synaffix agree to antibody-drug conjugate deal worth up to $150M
The Dutch biotech Synaffix has been active on the deal front for the past few years. And it’s not showing signs of stopping, hitting the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
